Trial · NCT00514709
Results by group86
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 86
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Hep B Pre-booster (N = 93, 103) | 81 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Hep B Pre-booster (N = 93, 103) | 80 | 0 to 0 | Participants |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Hep B Post-booster (N = 93, 105) | 91 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Hep B Post-booster (N = 93, 105) | 103 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-PRP Pre-booster (N = 93, 105) | 78 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-PRP Pre-booster (N = 93, 105) | 105 | 0 to 0 | Participants |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-PRP Post-booster (N = 93, 105) | 93 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-PRP Post-booster (N = 93, 105) | 105 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Diphtheria Pre-booster (N = 93, 105) | 72 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Diphtheria Pre-booster (N = 93, 105) | 68 | 0 to 0 | Participants |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Diphtheria Post-booster (N = 93, 105) | 93 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Diphtheria Post-booster (N = 93, 105) | 103 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Tetanus Pre-booster (N = 93, 105) | 93 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Tetanus Pre-booster (N = 93, 105) | 105 | 0 to 0 | Participants |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Tetanus Post-booster (N = 93, 105) | 93 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Tetanus Post-booster (N = 93, 105) | 105 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Pertussis 4-Fold increase (N = 89, 101) | 85 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Pertussis 4-Fold increase (N = 89, 101) | 100 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Pertussis booster response (N = 89, 101) | 87 | Participants | |
| Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Pertussis booster response (N = 89, 101) | 101 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00514709/results